Skip to main content

Table 1 Characteristics of the clinical trials being assessed for participation rates

From: Who says “no” to participating in stroke clinical trials and why: an observational study from the Vancouver Stroke Program

Intervention Antithrombotic agent (#1) Antithrombotic agent (#2) Surgery Device
Trial design Randomized Randomized Randomized Non-randomized
Enrolment time window < 72 h from symptom onset < 6 months from symptom onset < 6 months from diagnosis asymptomatic < 6 months from symptom onset
Brief description of study Novel anticoagulant vs standard of care for secondary prevention of ischemic stroke Novel anticoagulant vs standard of care for secondary prevention of ischemic stroke Surgery plus medical management vs medical management alone for primary prevention of ischemic stroke 30-day external loop recorder to look for atrial fibrillation